Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALB | P02768 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | GALK1 | P51570 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477562 | 1.00 | CYP2C9 (0.76) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Phenprocoumon SCHEMBL28142123 | 0.90 | CYP2C9 (0.79) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| SCHEMBL1479347 | 0.88 | CYP2C9 (0.73) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| SCHEMBL20806 | 0.88 | CYP2C9 (0.73) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| SCHEMBL136434 | 0.88 | CYP2C9 (0.73) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL27497093 | 0.86 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL33543 | 0.86 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL29454369 | 0.86 | CYP2C9 (1.00) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| Acenocoumarol SCHEMBL14662100 | 0.85 | CYP2C9 (0.98) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 | |
| SCHEMBL1477912 | 0.84 | CYP2C9 (0.63) | CYP2C9NR1I2NR3C1ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| WO-2022171098-A1 | ARTIFICIAL SMALL MOLECULE INTERFERING PEPTIDE OF DAPK1 PHOSPHORYLATED SUBSTRATE AND PHARMACEUTICAL USE THEREOF | 北京欣安诚科技有限公司 | 2022-08-18 | — | — | WO | claimed |
| WO-2021078412-A1 | FRACTAL FORMULATIONS | MESSADEK JALLAL (BE) | 2021-04-29 | — | — | WO | claimed |
| EP-3263145-B1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS | BECTON DICKINSON CO (US) | 2021-01-20 | — | — | EP | claimed |
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| CN-105963153-B | Active compound and cosmetics or skin care item comprising blue copper victory peptide | 广州瑞朗生物科技有限公司 | 2019-06-11 | — | — | CN | claimed |
| CN-109414452-A | Cyclodextrins as procoagulants | 桑昆血液供给基金会 | 2019-03-01 | — | — | CN | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| US-20060286614-A1 | METHOD FOR MONITORING COAGULABILITY AND HYPERCOAGULABLE STATES | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2006-12-21 | — | — | US | claimed |
| EP-1599190-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | Glenmark Pharmaceuticals Limited (IN) | 2005-11-30 | — | — | EP | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| EP-1368661-A2 | MONITORING SOLUABLE ENDOTHELIAL PROTEIN C RECEPTOR LEVELS IN ANTICOAGULANT THERAPY | Oklahoma Medical Research Foundation (US) | 2003-12-10 | — | — | EP | claimed |
| EP-1245247-A1 | Biocidal locks | Biolink Corporation (US) | 2002-10-02 | — | — | EP | claimed |
| US-6451339-B2 | DRUG DELIVERY | LIPOCINE, INC. | 2002-09-17 | — | — | US | claimed |
| WO-2002066981-A2 | MONITORING SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR LEVELS IN ANTICOAGULANT THERAPY | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2002-08-29 | — | — | WO | claimed |
| US-6350251-B1 | Biocidal locks | BIOLINK CORPORATION | 2002-02-26 | — | — | US | claimed |
| US-4334020-A | Method of producing L-glutamic acid by fermentation | AJINOMOTO COMPANY INCORPORATED (JP) | 1982-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | CYP2C9 4462/4885NR1I2 4117/4885NR3C1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.